HOME >> MEDICINE >> NEWS
Muscular dystrophy mouse model yields potential growth factor treatment

An altered mouse model of Duchenne muscular dystrophy, developed to have high levels of insulin-like growth factor I (IGF-I), has shown increases in muscle mass of at least 40 percent and other changes that could herald a possible treatment for secondary symptoms of the disease in humans. The new mouse, developed with support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the Muscular Dystrophy Association, has also resulted in reduced amounts of muscle-replacing fibrous tissue and enhanced biological pathways associated with muscle regeneration.

Duchenne muscular dystrophy, a genetic muscle-wasting disease caused by mutations in the gene for the protein dystrophin, results in repeated cycles of muscle damage and insufficient muscle regeneration, leading to gradual replacement of muscle by fibrous tissue. Since IGF-I is known to help regenerate muscle and enhance biological pathways for making proteins, the University of Pennsylvania's H. Lee Sweeney, M.D., and his colleagues tested its effects by creating a new mouse model a cross between a strain with muscular dystrophy symptoms and another with high levels of IGF-I. The hybrid mouse showed not only increases in muscle mass and muscle force generation, but also reduced muscle cell death, a combination that could have significant treatment implications.

"This is indeed good news for the muscular dystrophy community," said Stephen I. Katz, M.D., Ph.D., director of NIAMS. "The mouse model has helped our efforts against this disease more than once, and it looks like the search for answers has moved to another level."

The new mouse model offers an additional potential benefit, says Dr. Sweeney. "The combination of better muscle regeneration and less muscle wasting could lead to a better muscle capacity over time.

Less muscle effort would be needed to produce a required force, s
'"/>

Contact: Ray Fleming
flemingr@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
22-May-2002


Page: 1 2

Related medicine news :

1. McCaw/Muscular Dystrophy Association fund supports UW recruitment of internationally noted gene therapy researcher
2. Mayo Clinic researchers identify new form of muscular dystrophy in adults
3. New guideline: Corticosteroids recommended for duchenne muscular dystrophy
4. New centers boost muscular dystrophy research
5. Muscle stem cells show promise against muscular dystrophy in mouse model
6. Enzyme halts muscle waste in mouse models of most-common childhood muscular dystrophy
7. University of Pittsburgh researcher provides first-ever definition of HIV-associated lipodystrophy
8. UT Southwestern to study lipodystrophy syndrome in HIV-infected patients
9. UI study identifies mechanism that causes cardiomyopathy, exacerbates muscular dystrophy
10. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
11. UCSD-Utah team develops mouse model to test therapies for macular degeneration

Post Your Comments:
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 The ... present its annual awards at the International Symposium on ... will be held at the Hyatt Regency Bethesda in ... for their dedicated work and commitment to the mission ... the Year Award will be presented to Miriam Ratner. ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... Orlando, FL (PRWEB) February 28, 2015 ... community organization has sponsored visitor health insurance programs for ... 25 years. Most Indian elderly parents traveling to the ... conditions such as diabetes and blood pressure. These diseases ... do not even list them as medical conditions. There ...
(Date:2/28/2015)... Flagstaff, AZ (PRWEB) February 28, 2015 ... drug and alcohol treatment center , and current student ... State University, has implemented a weekly forum in psychoeducation ... high school in Flagstaff, AZ as part of her ... a big need for support and counseling at the ...
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an ... Scammers To Steal Your Data , which stresses the ease ... a DIY phishing kit, or any kind of malware kit ... important point about how everyone’s cyber security is intertwined when ... compromising legitimate content management systems or blogs in order to ...
Breaking Medicine News(10 mins):Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
(Date:2/27/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the fourth quarter and full year ended December 31, ... for PTC. We are now a growing commercial-stage biopharma ... the rare disease space," stated Stuart W. Peltz, Ph.D., ... to bring the first treatment for Duchenne muscular dystrophy ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, ... developing octreotide capsules, its lead product for the orphan ... million Series E financing round. Participants in the financing ... and an undisclosed blue chip public investment fund, as ... Med Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... CHICAGO, Ill. , Feb. 26, 2015 /PRNewswire/ ... that 15 abstracts of studies in its neuroscience ... presentation during the 67 th American Academy ... D.C. , from April 18-25. The accepted ... product, DUOPA, in addition to investigational treatments in ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
Cached News: